EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Aurora-A promotes lenvatinib resistance experimentally through hsa-circ-0058046/miR-424-5p/FGFR1 axis in hepatocellular carcinoma

Mubalake Abudoureyimu, Ni Sun, Weiwei Chen, Xinrong Lin, Fan Pan, Rui Wang iD

International Journal of Immunopathology and Pharmacology · 2025

DOI: 10.1177/03946320251316692 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Immunopathology and Pharmacology, 2025. Verfasst von Mubalake Abudoureyimu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Affiliated Jinling Hospital, Medical School, Nanjing University, Nanjing, China. Hauptthemen laut MEDLINE: Quinolines, Carcinoma, Hepatocellular, Liver Neoplasms, Phenylurea Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to investigate whether the dysregulation of Aurora-A is involved in lenvatinib resistance in hepatocellular carcinoma.

Methods

Bioinformatics tools and drug sensitivity assays were used to investigate the association between Aurora-A expression level and lenvatinib resistance in hepatocellular carcinoma cell lines. Cell function experiments had performed after treatment with lenvatinib and/or a selective Aurora-A inhibitor (MLN-8237). CircRNA microarray, RIP, RNA pull-down, and dual-luciferace reporter assay were performed to identify the downstream molecular mechanism of Aurora-A dysregulation.

Results

Aurora-A expression was positively correlated with lenvatinib resistance in hepatocellular carcinoma cells. The Aurora-A selective inhibitor MLN-8237, in combination with lenvatinib, synergistically inhibited hepatocellular carcinoma cell proliferation in vitro and vivo, suggesting the Aurora-A might be a potential therapeutic target for lenvatinib resistance. Mechanistically, Aurora-A induced FGFR1 expression through the hsa-circ-0058046/miR-424-5p/FGFR1 axis. Aurora-A promotes lenvatinib resistance through hsa-circ-0058046/miR-424-5p/FGFR1 axis in hepatocellular carcinoma cells. The simultaneous inhibition of FGFR1 by the Aurora-A inhibitor MLN-8237 and lenvatinib overcame lenvatinib resistance in hepatocellular carcinoma cells.

Conclusion

Collectively, our findings indicate that Aurora-A promotes lenvatinib resistance through the hsa-circ-0058046/miR-424-5p/FGFR1 axis in hepatocellular carcinoma (HCC) cells. These results suggest that Aurora-A may serve as a therapeutic target for HCC patients exhibiting lenvatinib resistance. Furthermore, the combination of lenvatinib and MLN-8237 shows potential for clinical trials aimed at overcoming lenvatinib resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinolinesCarcinoma, HepatocellularLiver NeoplasmsPhenylurea CompoundsDrug Resistance, NeoplasmMicroRNAsRNA, CircularAurora Kinase AReceptor, Fibroblast Growth Factor, Type 1HumansAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticPyrimidinesAntineoplastic AgentsProtein Kinase InhibitorsAzepinesMice, NudeSignal TransductionMice

Stichwörter der Autor:innen

Aurora-AAurora-A kinase inhibitorFGFR1MLN-8237hepatocellular carcinomahsa-circ-0058046lenvatinib resistancemiR-424-5p

Substanzen

lenvatinibQuinolinesPhenylurea CompoundsMicroRNAsRNA, CircularAurora Kinase AReceptor, Fibroblast Growth Factor, Type 1FGFR1 protein, humanMLN 8237Pyrimidines

Autor:innen und Institutionen

  • Department of Medical Oncology, Affiliated Jinling Hospital, Medical School, Nanjing University, Nanjing, China.
  • Department of Medical Oncology, Affiliated Jinling Hospital, Nanjing Medical University, Nanjing, China.

ORCID-Profile: Rui Wang

Zitieren

APA

Abudoureyimu, M., Sun, N., Chen, W., Lin, X., Pan, F., & Wang, R. (2025). Aurora-A promotes lenvatinib resistance experimentally through hsa-circ-0058046/miR-424-5p/FGFR1 axis in hepatocellular carcinoma. International Journal of Immunopathology and Pharmacology. https://doi.org/10.1177/03946320251316692

Vancouver

Abudoureyimu M, Sun N, Chen W, Lin X, Pan F, Wang R. Aurora-A promotes lenvatinib resistance experimentally through hsa-circ-0058046/miR-424-5p/FGFR1 axis in hepatocellular carcinoma. International Journal of Immunopathology and Pharmacology. 2025. doi:10.1177/03946320251316692

BibTeX
@article{Abudoureyimu2025,
  author = {Abudoureyimu, Mubalake and Sun, Ni and Chen, Weiwei and Lin, Xinrong and Pan, Fan and Wang, Rui},
  title = {Aurora-A promotes lenvatinib resistance experimentally through hsa-circ-0058046/miR-424-5p/FGFR1 axis in hepatocellular carcinoma},
  journal = {International Journal of Immunopathology and Pharmacology},
  year = {2025},
  doi = {10.1177/03946320251316692}
}
Kostenlos starten →